Key Goals With Using Iomab-B in Older Patients With R/R AML

Sergio A. Giralt, MD, deputy division head, Division of Hematologic Malignancies; Melvin Berlin Family Chair in Multiple Myeloma at Memorial Sloan Kettering Cancer Center discusses the key goals of the SIERRA trial (NCT02665065) which evaluated the safety and efficacy of I apamistamab (Iomab-B) versus conventional chemotherapy for the treatment of older patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

According to Giralt, the key goals of the SIERRA study was to determine if Iomab-B followed by a reduced intensity conditioning regimen of fludarabine and low dose total body irradiation (TBI) would be associated with better outcomes in the 6 months post-transplant when compared to conventional chemotherapy.

In total, 150 patients were randomized 1:1 between the experimental and control arms. If patients achieved a complete remission, they were able to go onto a reduced intensity conditioning regimen, according to Giralt.

0:08 | The key goal for the SIERRA study was to determine and to demonstrate that Iomab-B followed by a reduced intensity conditioning regimen of fludarabine and low dose TBI would be associated with better outcomes defined as being in a sustained complete remission for more than 6 months after transplant then conventional chemotherapy followed by a regular transplant. So, these were 150 patients that were randomized equally to Iomab-B versus conventional chemotherapy. Patients with Iomab-B would go to a fludarabine low dose TBI conditioning regimen, and then an allogeneic transplant with a matched sibling or an unrelated donor. Patients in the control arm would get conventional chemotherapy. And if they achieve the complete remission, they would then go on to a reduced intensity conditioning regimen.